BioRestorative Therapies, Inc. (BRTX) Fair Value 2026

BRTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-28, BioRestorative Therapies, Inc. (BRTX) trades at $0.20. QOC: 6.3/10. Value Trap Risk: 32/100 (LOW). 1/13 models active.

Key Facts

Ticker
BRTX
Price
$0.20
Quality Score
6.3/10
Value Trap Risk
32/100
Models Active
1/13
Last Updated
Strength: Dynamic NAV suggests +224.2% upside with 51% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give BRTX?

1 Intrinsic Value Models vs. Current Price ($0.20)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.65 +224.2%

All Models Active

All 1 models are displayed above.

What Is BioRestorative Therapies, Inc. (BRTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BioRestorative Therapies, Inc. is potentially undervalued at its current price of $0.20. Based on our 13-model framework, BioRestorative Therapies, Inc.'s intrinsic value is estimated at a median fair value of $0.65 — representing +224.2% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About BRTX?

1 of 13 models are currently active for BRTX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does BRTX Rank in Biotechnology?

Among 625 Biotechnology stocks, BRTX ranks #116 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

BioRestorative Therapies, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is BRTX a Value Trap?

CirclFi's Value Trap algorithm assigns BRTX a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for BioRestorative Therapies, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, BioRestorative Therapies, Inc. earns a quality score of 6.3/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BRTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BRTX's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BioRestorative Therapies, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CHRSCoherus Oncology, Inc.QOC 6.3ORMPOramed Pharmaceuticals Inc.QOC 6.3RLYBRallybio CorporationQOC 6.3PHATPhathom Pharmaceuticals, Inc.QOC 6.3SEPNSepterna, Inc.QOC 6.3LXRXLexicon Pharmaceuticals, Inc.QOC 6.3NEUPNeuphoria Therapeutics Inc.QOC 5.2IRONDisc Medicine, Inc.QOC 4.6CNXUConexeu Sciences Inc.QOC 3.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CHRS · ORMP · RLYB · PHAT · SEPN · LXRX · NEUP · IRON · CNXU · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to BRTX?

6 companies across all industries closest to BRTX’s Quality of Company score of 6.3/10.

PLTKPlaytika Holding Corp.QOC 6.3SRRESunrise Real Estate Group, Inc.QOC 6.3ASTSAST SpaceMobile, Inc.QOC 6.3ALVOAlvotechQOC 6.3LGPSLogProstyle Inc.QOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PLTK · SRRE · ASTS · ALVO · LGPS · NVDA

Where Does BRTX Sit in CirclFi's Biotechnology Rankings?

BRTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About BioRestorative Therapies, Inc.’s Valuation?

What is BioRestorative Therapies, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for BioRestorative Therapies, Inc. (BRTX). The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BRTX overvalued or undervalued right now?

At $0.20, 1 of 1 active models suggest BRTX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits BioRestorative Therapies, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.3 mean for BRTX?

BioRestorative Therapies, Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BRTX?

CirclFi analyzes BRTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BRTX a value trap in 2026?

BioRestorative Therapies, Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns BioRestorative Therapies, Inc. (BRTX) a Quality of Company score of 6.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/BRTX/ · Methodology
Primary sources for this BRTX valuation
  • Financial statements: BioRestorative Therapies, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001505497) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BRTX as of ; valuations recomputed .